MorphoSys cuts R&D from Constellation deal to focus on clinical-stage cancer drugs
MorphoSys is cutting the drug discovery and R&D work of Constellation Pharmaceuticals, a company it acquired lats year in a $1.7 billion deal. This consolidation […]
MorphoSys is cutting the drug discovery and R&D work of Constellation Pharmaceuticals, a company it acquired lats year in a $1.7 billion deal. This consolidation […]
Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. But what does […]
The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply […]
Shots: MorphoSys to acquire all of the outstanding shares of Constellation’s common stock for $34.00/ share in cash making a total equity value of $1.7B. […]
Shares in German biotech MorphoSys have gone on the slide after it announced a $1.7 billion deal to buy its US rival Constellation Pharma and […]
MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance […]
Copyright © 2024 | WordPress Theme by MH Themes